




A



B



C



D

Siglec-9 <sup>+</sup> TAMs subtypes	Low Siglec-9 <sup>+</sup> TAMs		High Siglec-9 <sup>+</sup> TAMs		PD-L1 subtypes	
	PD-L1 subtypes		PD-L1 subtypes			
Shared features	TP53 mutations				Negative	Positive
Particular features	CCND2 amp MLH1 mut MAML2 & MYC mut & exp Notch pathway activity	Nrf2 pathway activity	Siglec-9 exp WNT & HIPPO pathway activity	Siglec-9 exp KRAS mut Cell cycle & JAK-STAT & TGFβ & ATR/BRCA & Antigen presenting machinery & EGF & VEGF & Immune checkpoint & DNA damage immune response & IFN-γ response pathway activity Tertiary lymphoid structures pathway activity B cells	Negative	Positive
Possible therapies	BET inhibitor Notch inhibitor	Nrf2 pathway inhibitor	Siglec-9 targeted therapy WNT & HIPPO pathway inhibitor	Immune checkpoint inhibition + anti-TGFβ JAK-STAT inhibitor Siglec-9 targeted therapy	Negative	Positive